Raymond James Financial’s Vaxcyte PCVX Stock Holding History

Raymond James Financial’s Portfolio PCVX Stock Details PCVX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$21.5M	Buy	369,406 +109,011	+42%	+$5.92M	0.01%	1512
2026 Q1	$14.6M	Buy	260,395 +74,544	+40%	+$4.05M	﹤0.01%	1707
2025 Q4	$8.45M	Sell	185,851 -3,442	-2%	-$154K	﹤0.01%	2103
2025 Q3	$6.82M	Sell	189,293 -110,289	-37%	-$3.65M	﹤0.01%	2227
2025 Q2	$9.74M	Buy	299,582 +6,448	+2%	+$211K	﹤0.01%	1890
2025 Q1	$11.1M	Buy	293,134 +28,430	+11%	+$2.27M	﹤0.01%	1730
2024 Q4	$21.7M	Buy	+264,704	New	+$26.3M	0.01%	1246

Other funds holding PCVX

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Jupiter Topco New York $245B AUM

T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

RCM

RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return

DTC

Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return

Raymond James Financial's PCVX Position: Q2 2026 in Review

Raymond James Financial increased its Vaxcyte (PCVX) stake by 42% in Q2 2026, buying an estimated $5.92M and bringing the position to 369,406 shares worth $21.5M. The position accounts for 0.01% of the portfolio, ranked #1512.

Raymond James Financial first reported a position in PCVX in Q4 2024 and has held it in 7 quarters since. The position peaked at $21.7M in Q4 2024. 331 funds tracked by Wall St. Rank hold PCVX as of Q2 2026.

Raymond James Financial held 369,406 shares of Vaxcyte worth $21.5M as of Q2 2026.
Raymond James Financial bought 109,011 Vaxcyte shares in Q2 2026, an estimated $5.92M.
Vaxcyte made up 0.01% of Raymond James Financial's portfolio in Q2 2026, its #1512 holding.
Raymond James Financial first reported a position in Vaxcyte in Q4 2024 and has held it in 7 quarters since.
Raymond James Financial's Vaxcyte position peaked at $21.7M in Q4 2024.
331 funds tracked by Wall St. Rank held Vaxcyte as of Q2 2026.

Based on Raymond James Financial's 13F filing for Q2 2026, filed 14 Aug 2026.